BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 15154877)

  • 1. Protective effect of an oral adsorbent on renal function in chronic renal failure: determinants of its efficacy in diabetic nephropathy.
    Sanaka T; Akizawa T; Koide K; Koshikawa S
    Ther Apher Dial; 2004 Jun; 8(3):232-40. PubMed ID: 15154877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of combined treatment of oral sorbent with protein-restricted diet on change of reciprocal creatinine slope in patients with CRF.
    Sanaka T; Fujimoto K; Niwayama J; Nishimura H; Naito T; Higuchi C; Akizawa T; Koide K; Koshikawa S
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S35-7. PubMed ID: 12612949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients.
    Niwa T; Nomura T; Sugiyama S; Miyazaki T; Tsukushi S; Tsutsui S
    Kidney Int Suppl; 1997 Nov; 62():S23-8. PubMed ID: 9350673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the oral adsorbent AST-120 on tryptophan metabolism in uremic patients.
    Tsubakihara Y; Takabatake Y; Oka K; Shoji T; Togawa M; Okada N; Takahito I; Imai E
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S38-41. PubMed ID: 12612950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AST-120, an oral adsorbent, delays the initiation of dialysis in patients with chronic kidney diseases.
    Ueda H; Shibahara N; Takagi S; Inoue T; Katsuoka Y
    Ther Apher Dial; 2007 Jun; 11(3):189-95. PubMed ID: 17498000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of repeated oral administrations of the oral adsorbent AST-120 on serum creatinine and other markers of renal function. A randomized controlled study in patients with chronic kidney disease.
    Marier JF; Lee J; Kambhampati SR; Galitz L; Vargas R; Moberly J; Salazar DE
    Am J Nephrol; 2006; 26(2):136-41. PubMed ID: 16549905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible involvement of nuclear factor-kappaB inhibition in the renal protective effect of oral adsorbent AST-120 in a rat model of chronic renal failure.
    Komiya T; Miura K; Tsukamoto J; Okamura M; Tamada S; Asai T; Tashiro K; Kuwabara N; Iwao H; Yoshikawa J
    Int J Mol Med; 2004 Jan; 13(1):133-8. PubMed ID: 14654984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
    Siu YP; Leung KT; Tong MK; Kwan TH
    Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin converting enzyme inhibitor and chronic renal failure.
    Sitprija V; Lumlertgul D
    J Med Assoc Thai; 1993 Jul; 76(7):359-67. PubMed ID: 8089635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of angiotensin II receptor antagonist (losartan) on renal function, serum potassium and blood pressure in patients with advanced renal failure: differences between patients with a serum creatinine (SCr) level higher than 3 mg/dl and those with a lower SCr level].
    Nakayama M; Tanno Y; Otsuka Y; Takahashi H; Ikeda M; Katoh N; Yokoyama K; Yamamoto H; Tokutome G; Hosoya T
    Nihon Jinzo Gakkai Shi; 2002 Oct; 44(7):530-6. PubMed ID: 12476589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic effects of long-term administration of an oral adsorbent in patients with chronic renal failure: two-year study.
    Takahashi N; Kawaguchi T; Suzuki T
    Int J Urol; 2005 Jan; 12(1):7-11. PubMed ID: 15661048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral adsorbent AST-120 ameliorates tubular injury in chronic renal failure patients by reducing proteinuria and oxidative stress generation.
    Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Suzuki T; Ueda Y; Yamagishi S
    Metabolism; 2011 Feb; 60(2):260-4. PubMed ID: 20189611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An oral adsorbent, AST-120, combined with a low-protein diet and RAS blocker, for chronic kidney disease.
    Yorioka N; Kiribayashi K; Naito T; Ogata S; Yokoyama Y; Kyuden Y; Ogawa T; Wada K; Hayashi K; Hirabayashi A
    J Nephrol; 2008; 21(2):213-20. PubMed ID: 18446716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of oral adsorbent AST-120 on the progression of chronic renal failure: a randomized controlled study.
    Owada A; Nakao M; Koike J; Ujiie K; Tomita K; Shiigai T
    Kidney Int Suppl; 1997 Dec; 63():S188-90. PubMed ID: 9407455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AST-120 treatment in pre-dialysis period affects the prognosis in patients on hemodialysis.
    Ueda H; Shibahara N; Takagi S; Inoue T; Katsuoka Y
    Ren Fail; 2008; 30(9):856-60. PubMed ID: 18925523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of a keto acid supplement on the course of chronic renal failure and nutritional parameters in predialysis patients and patients on regular hemodialysis therapy: the Hungarian Ketosteril Cohort Study.
    Zakar G;
    Wien Klin Wochenschr; 2001 Sep; 113(17-18):688-94. PubMed ID: 11603104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors of renal failure progression two years prior to dialysis.
    Mazouz H; Kacso I; Ghazali A; El Esper N; Moriniere P; Makdassi R; Hardy P; Westeel PF; Achard JM; Pruna A; Fournier A
    Clin Nephrol; 1999 Jun; 51(6):355-66. PubMed ID: 10404696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbonic adsorbent AST-120 retards progression of renal failure by additive effect with ACEI and protein restriction diet.
    Imai E; Takenaka M; Isaka Y; Moriyama T; Akagi Y; Kakuchi J; Fujii T; Ito T; Hori M; Horio M; Syoji T; Tsubakihara Y
    Clin Exp Nephrol; 2003 Jun; 7(2):113-9. PubMed ID: 14586729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.